Compare TG Therapeutics Inc (TGTX) vs Visa Inc (V) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Visa Inc — how do they compare? TG Therapeutics Inc trades at $54.06 (market cap $8.26B), while Visa Inc trades at $356.1 (market cap $685.71B). The key difference: Visa Inc is far larger — about 83× TG Therapeutics Inc's market cap, and Visa Inc pays a 0.74% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| TGTX | V | |
|---|---|---|
Market Cap | $8.26B | $685.71B |
Sector | Health | Financials |
52-Week High | $59.06 | $365.14 |
52-Week Low | $26.39 | $295.52 |
Enterprise Value | $8.50B | $696.30B |
Volume | — | 10,431,336 |
Dividend Yield | — | 0.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Visa (V) trades at $355.82, down 0.76% on the day, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $396.70. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $3.31 exceeding expectations. Revenue reached $40 billion in 2025, and net income margin stands at 51.68%, reflecting robust profitability. Recent news highlights Visa's expansion into AI-driven commerce and stablecoin partnerships, positioning it for future growth in digital payments.
Visa presents a favorable long-term investment opportunity due to its dominant market position, consistent earnings growth, and high profitability. Key risks include competitive pressures from fintech and regulatory scrutiny. With 85% of analysts rating it a buy and institutional ownership increasing, the stock offers upside potential, though investors should monitor execution on AI initiatives and macroeconomic factors affecting consumer spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Visa Inc
Visa Inc. operates a retail electronic payments network and manages global financial services. The Company also offers global commerce through the transfer of value and information among financial institutions, merchants, consumers, businesses, and government entities.
Read more on V →
